Novavax, Inc. (NVAX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.21: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 7.0/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Negative price momentum.
Novavax develops protein-based nanoparticle vaccines with its proprietary Matrix-M adjuvant platform. Its authorized COVID-19 Vaccine (Nuvaxovid) is commercialized through a Sanofi collaboration; Novavax pursues additional pipeline candidates and Matrix-M licensing deals. The... Read more
Sell if holding. Engine safety override at $8.21: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 7.0/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 7.0/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerSanofi CLA10-K Item 1A: 'Our existing collaboration, funding and supply agreements, including the Sanofi CLA and our APAs, do not assure success of our vaccine candidates or vaccines'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.21: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 7.0/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $7.63. Score 7.0/10, moderate confidence.
Take-profit target: $12.18 (+48.5% upside). Prior stop was $7.63. Stop-loss: $7.63.
Risk below floor (2.4 < 3.0).
Novavax, Inc. trades at a P/E of 3.1 (forward -7.9). TrendMatrix value score: 9.3/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax develops protein-based nanoparticle vaccines with its proprietary Matrix-M adjuvant platform. Its authorized...
Novavax develops protein-based nanoparticle vaccines with its proprietary Matrix-M adjuvant platform. Its authorized COVID-19 Vaccine (Nuvaxovid) is commercialized through a Sanofi collaboration; Novavax pursues additional pipeline candidates and Matrix-M licensing deals. The company had an accumulated deficit of $4.6B as of December 31, 2025.